X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Cipla with VENUS REMEDIES - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CIPLA vs VENUS REMEDIES - Comparison Results

CIPLA    Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CIPLA VENUS REMEDIES CIPLA/
VENUS REMEDIES
 
P/E (TTM) x 40.5 -4.6 - View Chart
P/BV x 3.7 0.2 2,167.4% View Chart
Dividend Yield % 0.5 0.0 -  

Financials

 CIPLA   VENUS REMEDIES
EQUITY SHARE DATA
    CIPLA
Mar-18
VENUS REMEDIES
Mar-18
CIPLA/
VENUS REMEDIES
5-Yr Chart
Click to enlarge
High Rs663126 526.6%   
Low Rs47961 784.0%   
Sales per share (Unadj.) Rs189.0301.8 62.6%  
Earnings per share (Unadj.) Rs17.6-24.9 -70.7%  
Cash flow per share (Unadj.) Rs34.02.5 1,337.1%  
Dividends per share (Unadj.) Rs3.000-  
Dividend yield (eoy) %0.50-  
Book value per share (Unadj.) Rs176.7293.3 60.3%  
Shares outstanding (eoy) m805.1212.34 6,524.5%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x3.00.3 975.0%   
Avg P/E ratio x32.5-3.8 -863.2%  
P/CF ratio (eoy) x16.836.7 45.7%  
Price / Book Value ratio x3.20.3 1,013.4%  
Dividend payout %17.10-   
Avg Mkt Cap Rs m459,7241,154 39,844.6%   
No. of employees `00023.60.9 2,552.4%   
Total wages/salary Rs m26,901393 6,843.3%   
Avg. sales/employee Rs Th6,446.14,026.1 160.1%   
Avg. wages/employee Rs Th1,139.4425.0 268.1%   
Avg. net profit/employee Rs Th600.0-331.8 -180.8%   
INCOME DATA
Net Sales Rs m152,1933,724 4,086.7%  
Other income Rs m3,57723 15,895.6%   
Total revenues Rs m155,7693,747 4,157.6%   
Gross profit Rs m28,264395 7,159.0%  
Depreciation Rs m13,228338 3,910.2%   
Interest Rs m1,142354 322.4%   
Profit before tax Rs m17,470-275 -6,345.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m-280-   
Extraordinary Inc (Exp) Rs m-7750-   
Tax Rs m2,50132 7,914.9%   
Profit after tax Rs m14,166-307 -4,615.7%  
Gross profit margin %18.610.6 175.2%  
Effective tax rate %14.3-11.5 -124.7%   
Net profit margin %9.3-8.2 -112.9%  
BALANCE SHEET DATA
Current assets Rs m108,1412,638 4,099.9%   
Current liabilities Rs m38,3222,305 1,662.8%   
Net working cap to sales %45.98.9 513.0%  
Current ratio x2.81.1 246.6%  
Inventory Days Days97135 71.6%  
Debtors Days Days7446 160.6%  
Net fixed assets Rs m109,4114,871 2,246.3%   
Share capital Rs m1,610123 1,304.9%   
"Free" reserves Rs m140,6823,496 4,024.5%   
Net worth Rs m142,2923,619 3,931.7%   
Long term debt Rs m36,6211,374 2,664.5%   
Total assets Rs m228,6067,509 3,044.6%  
Interest coverage x16.30.2 7,307.3%   
Debt to equity ratio x0.30.4 67.8%  
Sales to assets ratio x0.70.5 134.2%   
Return on assets %6.70.6 1,060.7%  
Return on equity %10.0-8.5 -117.4%  
Return on capital %10.01.6 629.2%  
Exports to sales %32.80-   
Imports to sales %013.9 0.0%   
Exports (fob) Rs m49,883NA-   
Imports (cif) Rs mNA517 0.0%   
Fx inflow Rs m51,6910-   
Fx outflow Rs m21,033517 4,072.3%   
Net fx Rs m30,658-517 -5,935.6%   
CASH FLOW
From Operations Rs m14,628514 2,843.6%  
From Investments Rs m-8,540-123 6,937.5%  
From Financial Activity Rs m-3,855-387 995.8%  
Net Cashflow Rs m2,4314 57,883.3%  

Share Holding

Indian Promoters % 16.0 32.9 48.7%  
Foreign collaborators % 20.8 0.0 -  
Indian inst/Mut Fund % 12.2 0.2 6,777.8%  
FIIs % 23.7 0.6 4,086.2%  
ADR/GDR % 1.1 0.0 -  
Free float % 26.2 66.4 39.5%  
Shareholders   161,166 20,121 801.0%  
Pledged promoter(s) holding % 0.0 36.4 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CIPLA With:   DIVIS LABORATORIES  WOCKHARDT LTD.  AUROBINDO PHARMA  PLETHICO PHARMA  GLENMARK PHARMA  

Compare CIPLA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 170 Points Lower, Realty and FMCG Stocks Witness Selling(Closing)

After opening the day on a positive note, share markets in India witnessed volatile trading activity and ended in red.

Related Views on News

CIPLA at 52 Week High; BSE 500 Index Flat (Market Updates)

Sep 19, 2018 | Updated on Sep 19, 2018

CIPLA share price has hit a 52-week high. It is presently trading at Rs 678. BSE 500 Index is up by 0.2% at 15,303. Within the BSE 500, CIPLA (up 1.6%) and DCM SHRIRAM (up 5.3%) are among the top gainers, while top losers are TECHNO ELECTRIC and JET AIRWAYS.

VENUS REMEDIES Announces Quarterly Results (1QFY19); Net Profit Down 756.1% (Quarterly Result Update)

Aug 20, 2018 | Updated on Aug 20, 2018

For the quarter ended June 2018, VENUS REMEDIES has posted a net profit of Rs 56 m (down 756.1% YoY). Sales on the other hand came in at Rs 655 m (down 16.2% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

In a Crisis, if Petrol Prices Hit Rs 100, This Stock Could Be a Good Buy(The 5 Minute Wrapup)

Sep 6, 2018

The rise in the crude oil price is a major reason for the fall in the market. If crude oil prices keep on rising, what will happen to stocks?

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

The Secret Of Mirae Asset India Equity Fund's Increasing Popularity(Outside View)

Sep 7, 2018

The prudent investment strategies followed at the fund house has helped Mirae Asset India Equity Fund earn a tag of being a consistent performer, which is in turn gaining popularity among investors.

Hurricanes Threaten Oil Spike, but the Saudis are Selling...(Vivek Kaul's Diary)

Sep 6, 2018

Oil prices are rising and could go even more higher amid rising tensions in Middle East.

Should You Be Worried About the Rising Dollar?(Chart Of The Day)

Sep 7, 2018

While the rupee has deprecated by about 5% annually since 1990 against the dollar, the BSE Sensex has returned 14% annually in the same period.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

CIPLA SHARE PRICE


Sep 19, 2018 (Close)

TRACK CIPLA

CIPLA - TTK HEALTHCARE COMPARISON

COMPARE CIPLA WITH

MARKET STATS